Bad expression influences time to androgen escape in prostate cancer

BJU International

Volumn 100, Issue 3, 2007, Pages 691-696

  Teo, Katy ^a   Gemmell, Lisa ^a   Mukherjee, Rono ^a   Traynor, Pamela ^a   Edwards, Joanne ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Bad; Bax; Bcl 2; Bcl xL; Prostate cancer

Indexed keywords

ANDROGEN; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; RELAPSE; RETROSPECTIVE STUDY; SCORING SYSTEM; STATISTICAL SIGNIFICANCE;

AGED; ANDROGEN ANTAGONISTS; ANDROGENS; COHORT STUDIES; GENES, BCL-2; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT FAILURE;

EID: 34547621769     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07001.x     Document Type: Article

References (31)

1. Cancer Research UK. Available at: http://www.cancer-research-uk.org. Accessed April 2007
2. Huggins C, Hodges CV. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941 1 : 293 7
3. Edwards J, Bartlett JM. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: modifications to the androgen receptor. BJU Int 2005 95 : 1320 6
4. Bracarda S, de Cobelli O, Greco C et al. Cancer of the prostate. Crit Rev Oncol Hematol 2005 56 : 379 96
5. Bartlett JM, Brawley D, Grigor K, Munro AF, Dunne B, Edwards J. Type I receptor tyrosine kinases are associated with hormone escape in prostate cancer. J Pathol 2005 205 : 522 9
6. Edwards J, Traynor P, Munro AF, Pirret CF, Dunne B, Bartlett JM. The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer. Clin Cancer Res 2006 12 : 123 30
7. Edwards J, Krishna NS, Witton CJ, Bartlett JM. Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin Cancer Res 2003 9 : 5271 81
8. Datta SR, Dudek H, Tao X et al. Akt phosphorylation of Bad couples survival signals to the cell-intrinsic death machinery. Cell 1997 91 : 231 41
9. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner for Bcl-xL and Bcl-2, displaces Bax and promotes cell death. Cell 1995 80 : 285 91
10. Xiao D, Singh SV. Diallyl trisulfide, a constituent of processed garlic, inactivates Akt to trigger mitochondrial translocation of Bad and caspase-mediated apoptosis in human prostate cancer cells. Carcinogenesis 2006 27 : 533 40
11. Chao OS, Clement MV. Epidermal growth factor and serum activate distinct pathways to inhibit the BH3 only protein in prostate carcinoma LNCaP cells. Oncogene 2006 25 : 4458 69
12. Ichinose M, Liu X, Hagihara N, Youle RJ. Extracellular bad fused to toxin transport domains induces apoptosis. Cancer Res 2002 62 : 1433 8
13. Kelekar A, Chang BS, Harlan JE, Fesik SW, Thompson CB. Bad is a BH3 domain-containing protein that forms an inactivating dimmer with Bcl-xL. Mol Cell Biol 1997 17 : 7040 6
14. Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ. Role of PI3K signalling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 2001 142 : 4795 805
15. Djavan B, Moul JW, Zlotta A, Remzi M, Ravery V. PSA progression following radical prostatectomy and radiation therapy: new standards in the new millennium. Eur Urol 2003 43 : 12 27
16. Cannings E, Kirkegaard T, Tovey SM, Dunne B, Cooke TG, Bartlett JM. Bad expression predicts outcome in patients treated with tamoxifen. Breast Cancer Res Treat 2006 102 : 173 9
17. Baron S, Manin M, Beaudoin C et al. Androgen receptor mediates non-genomic activation of phosphatidylinositol 3-OH kinase in androgen-sensitive epithelial cells. J Biol Chem 2004 279 : 14579 86
18. Willis SN, Adams JM. Life in the balance: how BH3-only proteins induce apoptosis. Curr Opin Cell Biol 2005 17 : 617 625
19. Oltersdorf T, Elmore SW, Shoemaker AR et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005 435 : 677 81
20. Zhang Y, Yu J, Unni E et al. Monogene and polygene therapy for the treatment of experimental prostate cancers by use of apoptotic genes bax and bad driven by the prostate-specific promoter ARR(2)PB. Hum Gene Ther 2002 13 : 2051 64
21. Bruckheimer EM, Spurgers K, Weigel NL, Logothetis C, McDonnell TJ. Regulation of bcl-2 expression by dihydrotestosterone in hormone sensitive LNCaP-FGC prostate cancer cells. J Urol 2003 169 : 1553 7
22. McDonnell TJ, Troncoso P, Brisbay SM et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992 52 : 6940 4
23. Catz SD, Johnson JL. Bcl-2 in prostate cancer: a minireview. Apoptosis 2003 8 : 29 37
24. Zellweger T, Ninck C, Bloch M et al. Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 2005 113 : 619 28
25. Lebedeva I, Rando R, Ojwang J, Cossum P, Stein CA. Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity. Cancer Res 2000 60 : 6052 60
26. Gleave M, Tolcher A, Miyake H et al. Progression to androgen independence is delayed by adjuvant treatment with antisense bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumour model. Clin Cancer Res 1999 5 : 2891 8
27. Chi KN, Gleave ME, Klasa R et al. A phase I dose-finding study of combined treatment with an antisense bcl-2 oligonucleotide (Genesense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res 2001 7 : 3920 7
28. Yamanaka K, Rocchi P, Miyake H et al. A novel antisense oligonucleotide inhibiting several antiapoptotic bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. Mol Cancer Ther 2005 4 : 1689 98
29. Eisenmann KM, VanBrocklin MW, Staffend NA, Kitchen SM, Koo HM. Mitogen-activated protein kinase pathway-dependent tumor-specific survival signalling in melanoma cells through inactivation of the proapoptotic protein bad. Cancer Res 2003 63 : 8330 7
30. Yang X, Liu L, Sternberg D et al. The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated Bad phosphorylation at serine 112. Cancer Res 2005 65 : 7338 47
31. Sastry KS, Karpova Y, Kulik G. Epidermal growth factor protects prostate cancer cells from apoptosis by inducing Bad phosphorylation via redundant signaling pathways. J Biol Chem 2006 281 : 27367 77